Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Perrigo Co Confirms FDA Tentative Approval For OTC Version Of Omeprazole And Sodium Bicarbonate Capsules
Perrigo Co announced that it has received tentative approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) to market over-the-counter (OTC) omeprazole and sodium bicarbonate capsules 20mg/1100mg, the store brand equivalent to Merck & Co.’s Zegerid OTC. The Company expects to launch the product on the date when market formation occurs.
Latest Key Developments in Pharmaceuticals
- Wai Yuen Tong Medicine Holdings Ltd Comments On FY 2013 Earnings Guidance
- BioPorto A/S Updates on NGAL Patent Processing of Appeal in Opposition Case
- Astellas Pharma Inc Receives Marketing Authorization for VESOMNI from The Netherlands Medicines Evaluation Board
- Nordion Inc Enters Into Agreement To Divest Targeted Therapies Business To BTG Plc
- Share this
- Link this
- Digg this
Follow Reuters